Feed VCEL
VC

Vericel

VCEL · NASDAQ

$40.02 +1.19% (+$0.47)
1M -5.39%
Market Cap $2.05B
P/E Ratio 84.61x
Div. Yield -
ROE 6.91%

Bulios Fair Price

$31.73

20.7% downside

Current Price

$40.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, VCEL is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
16 /100
Expensive
P/FCF 41.28x
P/S 6.69x
P/B 5.54x
Growth
100 /100
Growing
FCF growth 34.86%
Book val. growth 22.64%
Rev. growth 18.90%
Profitability
66 /100
Moderate
Net margin 7.91%
Op. margin 5.95%
FCF margin 16.21%
Quality
31 /100
Poor
ROE 6.91%
ROA 4.82%
Asset turnover 0.61x
Debt
100 /100
Low
Current ratio 5.04x
Int. coverage 40.17x
Net debt/EBITDA -0.85x
Stability
56 /100
Moderate
Rev. volatility 2.13%
EPS volatility 189.95%
Profitable years 2

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about VCEL
Online

About the company

Vericel Corporation is a biotechnology company that specializes in the development and commercialization of advanced therapies for tissue regeneration. The company primarily focuses on treating severe wounds, burns, and orthopedic conditions, offering autologous cell therapies that use a patient’s own cells to support healing and regeneration. Its key products include Epicel, a therapy for burn treatment, and Carticel, a cell therapy for cartilage repair.

Sector

Healthcare

Industry

Biotechnology

CEO

Dominick C. Colangelo

Employees

398

Headquarters

Burlington

Upcoming events

05 NOV

Earnings

Upcoming earnings report

45d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.